Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours.

The anti-ErbB2 antibody trastuzumab is used for the treatment of patients with advanced breast cancer, resulting in a response rate of 40-60%. Coupling with a cytotoxic nuclide, e.g. alpha-emitting 211At, may further increase tumour response. The tumour-targeting properties of trastuzumab, astatinated using N-succinimidyl-para-(tri-n-methylstannyl)-benzoate, were evaluated and compared with those of radioiodinated trastuzumab in this study. We found that astatinated trastuzumab retains high specificity towards ErbB2. While the immunoreactive fraction of radioiodinated trastuzumab was higher than that of astatinated trastuzumab (76+/-9% versus 54+/-28%), both radioconjugates showed high affinity (KD 0.75+/-0.16 nM versus 1.8+/-0.3 nM). A growth inhibition study indicated a dose-dependent cell deactivation, in which approximately 74 cell-associated astatine decays per cell gave a survival fraction of 4.5+/-0.8x10(-4). Results of a comparative animal study on normal mice gave no indication that astatination would have any adverse effects on the biodistribution of the antibody. In conclusion, the results of the study suggest that astatinated trastuzumab is a promising candidate for treating ErbB2-expressing tumours.

[1]  S. Horning.  Future directions in radioimmunotherapy for B-cell lymphoma. , 2003, Seminars in oncology.

[2]  Thomas Beckers,et al.  Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. , 2003, Cancer research.

[3]  E. Blomquist,et al.  Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  H. Lundqvist,et al.  Direct astatination of a tumour-binding protein, human epidermal growth factor, using nido-carborane as a prosthetic group , 2003 .

[5]  D. Goldenberg.  Advancing role of radiolabeled antibodies in the therapy of cancer , 2003, Cancer Immunology, Immunotherapy.

[6]  L. Jacobsson,et al.  Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention. , 2003, Anticancer Research.

[7]  J. Horton.  Trastuzumab use in breast cancer: clinical issues. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[8]  K. Wester,et al.  HER-2 - A Possible Target for Therapy of Metastatic Urinary Bladder Carcinoma , 2002, Acta oncologica.

[9]  M. Pegram.  Docetaxel and herceptin: foundation for future strategies. , 2001, The oncologist.

[10]  H. Burrisiii.  Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer , 2001 .

[11]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[12]  M. Zalutsky,et al.  Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. , 2000, Current pharmaceutical design.

[13]  A. Wu,et al.  Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. , 2000, Bioconjugate chemistry.

[14]  R. Bast,et al.  Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. , 1999, Nuclear medicine and biology.

[15]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[16]  S. Larson,et al.  Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, Stem cells.

[18]  J. Koziorowski,et al.  A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for radioiodination of proteins , 1998 .

[19]  L. Jacobsson,et al.  Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. , 1998, Anticancer Research.

[20]  M. Zalutsky,et al.  Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. , 1998, Nuclear medicine and biology.

[21]  R. Bast,et al.  Radioiodinated antibody targeting of the HER-2/neu oncoprotein. , 1997, Nuclear medicine and biology.

[22]  M. Zalutsky,et al.  Targeted therapy using alpha emitters. , 1996, Physics in medicine and biology.

[23]  H. Figge,et al.  Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. , 1995, American journal of obstetrics and gynecology.

[24]  Ø. Bruland,et al.  Radiolysis of radioimmunoconjugates. Reduction in antigen-binding ability by α-particle radiation , 1995 .

[25]  R. Vessella,et al.  Preparation and evaluation of para-[211At]astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F(ab')2. In vivo distribution comparison with para-[125I]iodobenzoyl labeled A6H F(ab')2. , 1993, Nuclear medicine and biology.

[26]  N. Lemoine,et al.  Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.

[27]  D. Slamon,et al.  Radiolabeled antibody targeting of the HER-2/neu oncoprotein. , 1992, Cancer research.

[28]  D. Wilbur,et al.  Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate. , 1991, Bioconjugate chemistry.

[29]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[30]  A. Ullrich,et al.  Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.

[31]  Richard B. Firestone,et al.  Table of Radioactive Isotopes , 1986 .

[32]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[33]  J. Carlsson,et al.  Radiation effects on cultured human lymphoid cells. Analysis using the growth extrapolation method. , 1981, Acta radiologica. Oncology.

[34]  I. Pastan,et al.  Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. , 1980, The Journal of biological chemistry.

[35]  M. Fox,et al.  Minimum clone size for estimating normal reproductive capacity of cultured cells. , 1968, The British journal of radiology.